Search hospitals

>

Pennsylvania

>

Pittsburgh

University of Pittsburgh Medical Center

Claim this profile

Pittsburgh, Pennsylvania 15213

Global Leader in Cancer

Global Leader in Lung Cancer

Conducts research for Heart Failure

Conducts research for Breast Cancer

Conducts research for Pancreatic Cancer

1068 reported clinical trials

124 medical researchers

Photo of University of Pittsburgh Medical Center in PittsburghPhoto of University of Pittsburgh Medical Center in Pittsburgh

Summary

University of Pittsburgh Medical Center is a medical facility located in Pittsburgh, Pennsylvania. This center is recognized for care of Cancer, Lung Cancer, Heart Failure, Breast Cancer, Pancreatic Cancer and other specialties. University of Pittsburgh Medical Center is involved with conducting 1,068 clinical trials across 1,297 conditions. There are 124 research doctors associated with this hospital, such as Liza C. Villaruz, Jason Luke, MD, Diwakar Davar, MD, and Adam Brufsky, MD.

Area of expertise

1

Cancer

Global Leader

University of Pittsburgh Medical Center has run 65 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage III
FGFR3 positive
2

Lung Cancer

Global Leader

University of Pittsburgh Medical Center has run 48 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage III
KRAS positive

Top PIs

Clinical Trials running at University of Pittsburgh Medical Center

Breast Cancer

Cancer

Prostate Cancer

Lung Cancer

Adrenoleukodystrophy

Age-Related Macular Degeneration

Coronary Artery Disease

Small Cell Lung Cancer

Multiple Myeloma

Head and Neck Cancers

Image of trial facility.

Lasofoxifene and Abemaciclib vs Fulvestrant and Abemaciclib

for Breast Cancer

The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The main question the study aims to answer is: • To compare the efficacy of the combination of lasofoxifene and abemaciclib with that of fulvestrant and abemaciclib Participants will receive either receive 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day or the combination of fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day.

Recruiting

2 awards

Phase 3

12 criteria

Image of trial facility.

HER2 Assay

for Breast Cancer

This study will assess whether a quantitative, HER2 assay can accurately and reliably discriminate between responders and non-responders among patients with HER2 IHCI+ metastatic breast cancer who are receiving T-Dxd.

Recruiting

1 award

N/A

7 criteria

Image of trial facility.

PC14586

for Solid Tumors

This trial is testing a new oral drug, PC14586 (rezatapopt), alone and with pembrolizumab, in patients with advanced cancers that have a specific genetic mutation. The drug aims to fix a mutated protein to help control cancer growth. The study will determine the best dose and evaluate the drug's safety and effectiveness.

Recruiting

1 award

Phase 1 & 2

5 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at University of Pittsburgh Medical Center?

Where is University of Pittsburgh Medical Center located?

Who should I call to ask about financial aid or insurance network?

What insurance does University of Pittsburgh Medical Center accept?

What awards or recognition has University of Pittsburgh Medical Center received?